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Abstract
Background: So-Cheong-Ryong-Tang, a traditional Korean medicine, has been used empirically for the treatment
of asthma, allergic rhinitis, and colds for hundreds of years. However, its genotoxicity has been rarely examined.
Methods: We therefore investigated the genotoxicity of an aqueous extract of So-Cheong-Ryong-Tang (SCRT) in
two in vitro and one in vivo assays: a bacterial reverse mutation assay (Ames test), a chromosomal aberration assay,
and a micronucleus assay, respectively.
Results: In the bacterial reverse mutation assay, SCRT did not increase revertant colony numbers in Salmonella.
typhimurium strains (TA98, TA100, TA1535, and TA1537) or an Escherichia coli strain (WP2 uvrA) regardless of
metabolic activation or the duration of treatment. However, statistically significant differences in the incidence of
chromosomal aberrations following SCRT >4000 μg/mL were observed in Chinese hamster lung cells exposed with
or without an S9 enzyme and cofactor mixture.
Conclusions: These results suggest further genotoxic testing of SCRT, such as a comet assay, to ascertain its
generally recognized safety.
Keywords: So-Cheong-Ryong-Tang, Ames test, Chromosome aberration assay, Micronucleus assay, Acute toxicity
Background
The traditional herbal medicine So-Cheong-Ryong-Tang
(known as Xiao-Qing-Long-Tang in traditional Chinese
medicine and as Sho-seiryu-to in Japanese Kampo medi-
cine) is a mixture of eight herbal preparations (Herba
Ephedrae, Radix Paeoniae, Fructus Schisandrae, Tuber
Pinelliae, Asiasari Radix, Rhizoma Crudus Zingiberis,
Ramulus Cinnamomi, and Radix et Rhizoma Glycyrrhi-
zae). This mixture has long been used to treat allergic
rhinitis, bronchitis, and bronchial asthma [1]. So-
Cheong-Ryong-Tang has several pharmacological effects
such as antiallergic activity on airway inflammation in a
mouse model [2] and decreasing antigen-induced num-
bers of eosinophils and basophils [3].
The use of herbal prescriptions as primary therapeutics
or supplements for improving health-related conditions is
popular worldwide [4]. Traditional herbal medicines are
selected to accentuate the therapeutic activity of their
components, while attenuating the toxicity or side effects
of components from other herbs in the mixture [5]. Dur-
ing the past two decades, studies have demonstrated the
potential efficacy of SCRT as a treatment for asthma in
mouse [1, 2] and guinea pig [6] models, and in clinical
studies. To determine the safety of medicines, system-
atic toxicological studies must be performed using ex-
perimental models to predict toxicity and to set criteria
for selecting a safe dose in humans. Despite the popular
use of So-Cheong-Ryong-Tang in traditional Korea
medicine, no systematic evaluation of its genotoxic ef-
fects has been performed. Assessment of the genotoxic
properties of folk medicine is important because dam-
age to genetic material may lead to critical mutations
and may thereby increase the risk of diseases including
cancer [7]. Therefore, the purpose of the present study
was to evaluate the safety of an aqueous extract of So-
Cheong-Ryong-Tang (SCRT) and its genotoxicity and
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acute toxicity. We assessed these properties using the
standard battery of tests recommended by the Korea
Food and Drug Administration (KFDA): the bacterial
reverse mutation test (Ames test), the chromosome
aberration test, and the in vivo micronucleus test.
Methods
Reagents
Coumarin and cinnamic acid were purchased from
Sigma-Aldrich (St Louis, MO, USA). Albiflorin, paeoni-
florin, cinnamaldehyde, glycyrrhizin, and schizandrin
were obtained from Wako Pure Chemical Industries Ltd
(Osaka, Japan). Liquiritin was purchased from NPC Bio-
Technology (Daejeon, Korea). The purity of each com-
pound was determined as ≥98 % by HPLC analysis.
HPLC-grade reagents, water, methanol, and acetonitrile
were obtained from J.T. Baker (Phillipsburg, NJ, USA).
Acetic acid was purchased from Junsei (Tokyo, Japan). The
materials for preparing the aqueous extract of SCRT were
purchased from Kwangmyungdang Medicinal Herbs
(Ulsan, Korea). Voucher specimens (2012-KE13-1 to KE13-
8) have been deposited at the Herbal Formulation Research
Group, Korea Institute of Oriental Medicine (KIOM).
Preparation of standard and sample solutions
Standard stock solutions of eight compounds, albiflorin,
paeoniflorin, liquiritin, coumarin, cinnamic acid, cinna-
maldehyde, glycyrrhizin, and schizandrin (Figure 1) were
dissolved in methanol at concentrations of 1 mg/mL and
stored below 4 °C.
SCRT was formulated from eight herbs (Additional
file 1: Table S1, 72.0 kg) and was extracted with distilled
water at 100 °C for 2 h in herb extractor (COSMOS-660,
Kyungseo Machine Co, Inchon, Korea). The extract was
filtrated using a standard sieve (No. 270, 53 μm) and
freeze-dried (9.3 kg). The yield of extract was 12.9 %. Ly-
ophilized SCRT extract (200 mg) was dissolved in dis-
tilled water (20 mL). The solution was filtered through a
SmartPor GHP syringe filter (0.2 μm pore size, Woongki
Science, Seoul, Korea).
HPLC conditions
We performed a simultaneous analysis of extract com-
ponents using a Shimadzu LC-20A HPLC system
(Shimadzu, Kyoto, Japan), consisting of a solvent delivery
unit, an online degasser, a column oven, an autosampler,
and a photodiode array (PDA) detector. A data proces-
sor employed LCsolution software (version 1.24). The
analytical column used for separation was a Gemini C18
column (250 mm× 4.6 mm, particle size 5 μm; Phenom-
enex, Torrance, CA, USA) and was maintained at 40 °C.
The mobile phases consisted of 1.0 % (v/v) aqueous
acetic acid (A) and 1.0 % (v/v) acetic acid in acetonitrile
(B). The gradient flow was as follows: (A)/(B) = 85/15
(0 min)→ (A)/(B) = 35/65 (35 min)→ (A)/(B) = 0/100
(45 min; hold for 5 min)→ (A)/(B) = 85/15 (55 min; hold
for 15 min). The analysis was conducted at a flow rate of
1.0 mL/min with PDA detection at 230 nm, 254 nm, and
280 nm. The injection volume was 10 μL.
Acute oral toxicity test
To test the acute oral toxicity of SCRT, specific pathogen-
free Sprague Dawley rats of both sexes were obtained at
5 weeks of age from Orient Bio Co. (Seongnam, Korea)
and used after 1 week of quarantine and acclimatization.
This study was approved by KIOM’s Institutional Animal
Care and Use Committee (IACUC); it was performed at
the Korea Institute of Toxicology (KIT; Daejeon, Korea)
and conducted according to the guidelines of KIT’s
IACUC, which is accredited by AAALAC International
(1998) under the GLP Regulations for Nonclinical Labora-
tory Studies. A preliminary study showed that a single oral
administration of SCRT did not induce any toxic effect at
dose levels of 0 and 2000 mg/kg/day. Based on these re-
sults, a dose of 2000 mg/kg/day was selected as the toxico-
logical limited dose recommended by the Organization for
Economic Cooperation and Development (OECD) guide-
line (1997: Principles of Good Laboratory Practice).
Healthy male and female rats were assigned to groups of
five rats of each sex. SCRT was suspended in distilled
water, and the volume for application of a dose of
10 mL/kg body weight was calculated. The vehicle con-
trol rats received an equivalent volume of distilled water
only. All animals were observed, and mortality, clinical
signs, body weight changes, and gross findings were
recorded for 14 days.
Bacterial reverse mutation assay (Ames test)
The experimental methods used in the study were based
on the published reports by Maron and Ames [8, 9],
with minor modifications. Salmonella typhimurium
strains TA98 and TA1537 (to detect frame-shift muta-
gens), TA1535, and TA100, and Escherichia coli strain
WP2 uvrA (to detect base pair-substitution mutagens)
were obtained from Molecular Toxicology Inc. (Boone,
NC, USA) and used as the test strains. The bacterial
reverse mutation assay was performed as described
previously [10].
Chromosome aberration test
Chinese hamster lung (CHL) cells were obtained from
the American Type Culture Collection (Manassas, VA,
USA) in 2004. The chromosome aberration assay was
performed according to OECD guideline No. 473 “In
Vitro Mammalian Chromosome Aberration Test” [11]
and previously performed methods with minor modifica-
tion as described by Ishidate et al. [12] and Dean and
Danford [13].
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In vivo micronucleus test
The preliminary study showed that oral administration
of SCRT at a dose of 2000 mg/kg did not induce any
toxic effect (data not shown). The highest dose was de-
termined based on the dose range-finding study, and
2000 mg/kg, which was the limit dose for treatment up
to 14 days according to the OECD guidelines, was se-
lected as the maximum dose. Specific pathogen-free
male CrljOri:CD1 (ICR) mice weighing 27.2–30.0 g were
obtained from Orient Bio Co. (Seongnam, Korea) at
6 weeks old. Mice were used in experiments after 1
week of quarantine and acclimatization. This study was
reviewed and assessed by KIT’s IACUC. This micronu-
cleus test was conducted in accordance with OECD
guideline No. 474 “Mammalian Erythrocyte Micronu-
cleus Test” [14], with minor modifications. The micro-
nucleus test using mice was performed as described
previously [10].
Statistical analyses
Body weights are presented as mean ± standard deviation
(SD). All statistical analyses were performed with the
Path/Tox System (version 4.2.2) using an F test. The
statistical analyses for the in vitro chromosomal aberra-
tion results were conducted using a method described
by Richardson et al. [15]. The number of aberrant
metaphases (excluding gaps) and the number of [PP + ER]
were analyzed. The Fisher’s exact test was performed to
compare the vehicle control and to test item-treated
groups. Fisher’s exact test was used to compare the vehicle
and positive control groups. Differences were regarded as
significant at P < 0.05. No statistical analysis was per-
formed on the Ames test results. Statistical evaluation of
the in vivo micronucleus results was performed using the
method described by Lovell et al. [16] with minor modifi-
cation. In vivo micronucleus statistical analysis was con-
ducted as described previously [10].
Results
HPLC analysis
A chromatogram of SCRT was obtained using an HPLC-
PDA. Under optimized chromatography conditions,
eight constituents were eluted within 35 min in the con-
trol sample analysis using mobile phases comprising
solvent A (1.0 %, v/v acetic acid in water) and solvent B
(1.0 %, v/v acetic acid in acetonitrile).
The linearity of the peak area (y) versus concentration
(x, μg/mL) curve for each component was used to
masure the contents of the main components in SCRT
(Fig. 2a and b). Additional file 1: Table S2 showed the
calibration curves and correlation coefficients (r2) of 8
constituents. The retention times of the 8 components,
Fig. 1 Chemical structures of the eight main compounds found in SCRT
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Fig. 2 HPLC chromatograms of a standard mixture (a) and SCRT (b) at 230 nm (I), 254 nm (II), and 280 nm (III). Albiflorin (1), paeoniflorin (2),
liquiritin (3), coumarin (4), cinnamic acid (5), cinnamaldehyde (6), glycyrrhizin (7), and schizandrin (8)
Lee et al. BMC Complementary and Alternative Medicine  (2015) 15:235 Page 4 of 8
albiflorin, paeoniflorin, liquiritin, coumarin, cinnamic
acid, cinnamaldehyde, glycyrrhizin, and schzandrin were
8.88 min, 9.76 min, 11.59 min, 17.83 min, 20.83 min,
23.45 min, 29.37 min, and 31.83 min, respectively. Fig. 2a
and b shows the HPLC chromatogram of standard solution
and water extract of SCRT. The contents of 8 compounds
were 0.22–12.02 mg/g (Additional file 1: Table S3).
Acute oral toxicity test
No mortality or clinical symptoms of toxicity were ob-
served in rats of either sex in any group during the 14-
day observation period of the SCRT-treated group. The
body weight changes are summarized in Fig. 3. For both
sexes, the changes in body weight did not differ signifi-
cantly between treated with 2000 mg/kg/day of SCRT
and the vehicle control group. At the time of the sched-
uled autopsy, there were no abnormal observations
including for the lung, heart, thymus, stomach, liver,
adrenals, and spleen in the male or female rats given
2000 mg/kg/day of SCRT.
Bacterial reverse mutation assay (Ames test)
The positive controls showed significantly increased
numbers of revertant colonies, indicating that the assay
was valid. No positive mutagenic response was observed
in any of the S. typhimurium or E. coli strains tested
compared with the concurrent vehicle control groups
regardless of the presence (Fig. 4a) or absence (Fig. 4b)
of the S9 mixture up to 5000 μg/plate.
Chromosome aberration tests
According to our preliminary study (data not shown),
SCRT neither inhibited cell growth nor killed CHL cells.
We determined the concentration range (2000, 3000,
4000, 4500, and 5000 μg/mL) that was most compatible
with a good cell-proliferating ability and that produced a
sufficient number of metaphases for the confirmatory
assay. Therefore, we used 5000 μg/mL as the highest
exposure level and serial dilutions for further dose–re-
sponse tests.
There was a statistically significant increase in the num-
ber of metaphase cells with structural aberrations at 6 h or
22 h with or without the S9 mixture in the SCRT-treated
groups at 4000 μg/mL or 5000 μg/mL (Additional file 1:
Table S4) compared with the vehicle control group (P <
0.01). In the positive control groups, there were significant
increases in the number of aberrant metaphases. The
number of metaphases with structural aberrations in the
vehicle and positive control groups was within the range
established in the historical data of KIT (KIT, 2009). These
findings confirm that the methodologies used in this study
were valid. Therefore, under the conditions of this test,
SCRT showed a positive response in the chromosomal
aberration test.
Micronucleus test
No abnormal changes were observed in the general
appearance or body weight between the first and final
administrations in the vehicle control group, positive
control group, or the groups treated with 500, 1000, or
2000 mg/kg/day of SCRT (Additional file 1: Table S5).
The number of MNPCEs/2000 PCEs and PCE/(PCE +
NCE) did not increase significantly in the groups treated
with SCRT at 500, 1000, or 2000 mg/kg/day (Additional
file 1: Table S6). There was a significant increase in the
number of MNPCEs/2000 PCEs in the positive control
group, indicating that the present study was performed
under acceptable experimental conditions.
Discussion and conclusions
The long history of herbal prescriptions seems that
they are nontoxic and clinically effective. However, for
Fig. 3 Changes of mean body weight in male and female rats after single oral administration of SCRT at dose levels of 0 (○) and 2000 mg/kg
(●) in male rats and 0 (□) and 2000 mg/kg (■) in female rats. There were no significant differences in body weight between rats in the
SCRT-treated and control groups. Values are presented as mean ± SD
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Fig. 4 Effect of SCRT on bacterial reverse mutation assay (Ames test) (a) with (+S9 mix) and (b) without (−S9 mix) metabolic activation.
BP: Benzo(a)pyrene, SA: Sodium azide, 2-AA: 2-Aminoanthracene, 2-NF: 2-Nitrofluorene, 4NQO: 4-Nitroquinoline N-oxide, 9-AA: 9-Aminoacridine,
VC: vehicle control
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present medicinal therapeutics, there have been few
scientific studies undertaken to determine the safety of
traditional medicinal herbs. Therefore, concerns have
been raised about the lack of scientific evidence for the
safety of herbal medicines [17]. SCRT was proven to be
safe in a 90-day oral toxicity study in rats [18]. In a
series of safety evaluations for SCRT, a genotoxicity test
was conducted in the present work to check its capacity
for mutagenicity. Here, we performed to detect chromo-
some aberrations in CHL cells, a bacterial reverse muta-
tion test using the S. typhimurium/E. coli incorporation
assay (Ames test), and an in vivo micronucleus test recom-
mended by the KFDA. We evaluated acute toxicity using
the standard battery of tests recommended by the KFDA.
The present study was performed according to OECD
guidelines for the testing of chemicals in accordance with
modern Good Laboratory Practice Regulations.
In the acute toxicity test, a single oral dose of SCRT did
not cause any adverse effects at doses of up to 2000 mg/
kg/day. Genotoxicity tests have been used mainly for the
prediction of carcinogenicity of compounds because com-
pounds that are have the potential to cause carcinogenic
and/or mutagenic effects in humans [19, 20].
The Ames test has been extensively used to evaluate
mutagenic and carcinogenic risks. In the present Ames
test, there was no positive mutagenic response at any
concentration of SCRT up to 5000 μg/plate in any of the
S. typhimurium (TA100, TA1535, TA98, and TA1537) or
E. coli (WP2 uvrA) strains compared with the concur-
rent vehicle control groups regardless of the presence or
absence of the metabolic activation system (S9 mixture).
This indicates that SCRT is not mutagenic to bacterial
strains TA98, TA100, TA1535, TA1537, and WP2 uvrA.
The in vitro chromosomal aberration test is a widely
used assessment of genotoxicity. Many birth defects and
human genetic diseases are associated with abnormal
chromosome complements. In the chromosomal aberra-
tion test, statistically increases in the number of meta-
phases with structural aberrations at over 4000 μg/mL of
SCRT were seen in the presence or absence of the meta-
bolic activation system in CHL cells. The results of the
in vitro chromosomal aberration assay suggest that
SCRT can cause genetic disorders. However, SCRT con-
sists of eight different herbs, and each herb contains
various components, such as flavonoids. Some flavonoids
can induce cellular mutagenecity [21]. Therefore, it is
possible that the genotoxicity of SCRT observed in the
chromosomal aberration test is related to a specific sin-
gle component. An in vivo chromosomal aberration test
is thus warranted.
The micronucleus test is used to detect mutagenic
substances, thus altering the equitable distribution of
chromosomes [22]. In the micronucleus test using ICR
mice, no abnormal clinical signs in general appearance
and body weight were observed in the 500, 1000, or
2000 mg/kg/day SCRT treatment groups. SCRT did not
induce any significant increases in MNPCEs, and there
was no significant decrease in the PCE/(PCE + NCE) ra-
tio up to 2000 mg/kg in the SCRT treatment groups
compared with the vehicle control. From these results,
we conclude that SCRT did not induce mutagenesis
under the conditions of this study.
In conclusion, SCRT had no genotoxic effects (in the
Ames test and the in vivo micronucleus test) except in
the chromosomal aberration test, suggesting that SCRT
may cause mutations in chromosomes in vitro. Further de-
tailed experiments are needed to identify whether SCRT
contains any genotoxic component and, if so, the under-
lying mechanism(s) of genotoxicity.
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